Filter by

Latest From This Topic

New Delhi, August 28   
CCI direction: Sun, Ranbaxy to publish details of merger

Sun Pharma and Ranbaxy, which had entered into a $4-billion deal in April, have told the Bombay Stock Exchange that they will publish the details of the “proposed combination” within 10 wor... »

New Delhi, Aug 28  
Sun-Ranbaxy deal: Competition panel expands probe; seeks public scrutiny
Widening its scrutiny of the multi-billion dollar Sun Pharma-Ranbaxy deal, fair trade watchdog CCI has asked the two pharma majors to make public specific details of their proposed merger within t... »
Thursday, August 28, 2014
Intimation pertaining to communication dated Aug 27, 2014 received from the Competition Commission of India (CCI) in respect of the proposed combination between Sun Pharmaceutical Industries Ltd (Sun Pharma) and Ranbaxy Laboratories Ltd
Sun Pharmaceutical Industries Ltd has informed BSE that the Company is in receipt of direction under Section 29(2) of the Competition Act, 2002 from CCI directing Sun Pharma to publish the details... »

More Articles about:  Sun Pharmaceutical Industries Limited

Pages: «  2 3 4 5 6 »
Pages: «  2 3 4 5 6 »

More Articles about:  Sun Pharmaceutical Industries Limited

Browse topics

Track your company
Today's Poll
Is Harsh Vardhan's 'work on a holiday' plan feasible for doctors?
Can't say

Follow us on...

With money locked into projects, some firms are struggling to meet their day-to-day needs »

Rajalakshmi Nirmal and Radhika Merwin of the BL Research Bureau discuss the role of asset reconstruction companies (ARCs) in the banking sector and how they deal with bad loans.

Tweets @businessline


Exchange Rate

Dollar Spot Forward Rate

Open-Ended Mutual Funds

MCX-SX Currency Futures

NSE Currency Futures

Comments to: Copyright © 2014, The Hindu Business Line.